Eosinophil targeted therapy, particularly interleukin-5 (IL-5) and interleukin-13 (IL-13), has become an attractive option for EoE therapy due to its crucial role in proliferation and survival. The gene discussed is IL5; the disease is eosinophilic esophagitis.